ArticleFrontiers in oncology2026

Characterizing bleeding adverse events associated with BCR-ABL tyrosine kinase inhibitors: insights from FAERS reports.

Ranran Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.